Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSB | P07858 | 4/20 | 0.62 |
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25244521 | 0.88 | MEN1 (0.61) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL25288556 | 0.88 | MEN1 (0.61) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL24691246 | 0.87 | TAS1R3 (0.47) | CTSLCTSBCTSSTAS1R3TAS1R1 | |
| SCHEMBL24029390 | 0.87 | MEN1 (0.62) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL26230797 | 0.86 | ALB (0.55) | CTSLCTSBCTSS | |
| SCHEMBL25286907 | 0.86 | MEN1 (0.61) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL25286906 | 0.86 | MEN1 (0.61) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL23824277 | 0.85 | MEN1 (0.67) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL24208602 | 0.85 | TAS1R3 (0.69) | CTSLCTSBCTSSMEN1KMT2A | |
| SCHEMBL24113057 | 0.85 | MEN1 (0.64) | CTSLCTSBCTSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | CTSL 2/4885CTSB 27/4885CTSS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.